Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia

Daniela Cilloni; Sonia Carturan; Enrico Bracco; Valentina Campia; Valentina Rosso; Davide Torti; Chiara Calabrese; Valentina Gaidano; Pimjai Niparuck; Alessandra Favole; Elisabetta Signorino; Ilaria Iacobucci; Annalisa Morano; Luciana De Luca; Pellegrino Musto; Francesco Frassoni; Giuseppe Saglio

doi:10.1016/j.leukres.2013.01.014

Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia

Daniela Cilloni
, Sonia Carturan
, Enrico Bracco
, Valentina Campia
, Valentina Rosso
, Davide Torti
, Chiara Calabrese
, Valentina Gaidano
, Pimjai Niparuck
, Alessandra Favole
, Elisabetta Signorino
, Ilaria Iacobucci
, Annalisa Morano
, Luciana De Luca
, Pellegrino Musto
, Francesco Frassoni
, Giuseppe Saglio

Department of Medicine

Università degli Studi di Torino
Università di Bologna
Centro di Riferimento Oncologico della Basilicata IRCCS-CROB
Istituto Giannina Gaslini

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Chronic myelomonocytic leukemia (CMML) is a clonal disorder sharing features of myelodysplastic syndromes and chronic myeloproliferative neoplasms. Although rare chromosomal aberrations and point mutations are reported in CMML, the molecular defects underlying CMML are largely unknown. ROS1 encodes a tyrosine kinase that is abnormally expressed and translocated in brain and lung cancers. In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.

Original language	English
Pages (from-to)	520-530
Number of pages	11
Journal	Leukemia Research
Volume	37
Issue number	5
DOIs	https://doi.org/10.1016/j.leukres.2013.01.014
Publication status	Published - May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CMML
Chronic myeloproliferative neoplasms
Molecular target
Proliferation
ROS1
Tyrosine kinase

Access to Document

10.1016/j.leukres.2013.01.014

Cite this

Cilloni, D., Carturan, S., Bracco, E., Campia, V., Rosso, V., Torti, D., Calabrese, C., Gaidano, V., Niparuck, P., Favole, A., Signorino, E., Iacobucci, I., Morano, A., De Luca, L., Musto, P., Frassoni, F., & Saglio, G. (2013). Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leukemia Research, 37(5), 520-530. https://doi.org/10.1016/j.leukres.2013.01.014

@article{ad92b760e0754458a947e0f4b4b2c5ee,

title = "Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia",

abstract = "Chronic myelomonocytic leukemia (CMML) is a clonal disorder sharing features of myelodysplastic syndromes and chronic myeloproliferative neoplasms. Although rare chromosomal aberrations and point mutations are reported in CMML, the molecular defects underlying CMML are largely unknown. ROS1 encodes a tyrosine kinase that is abnormally expressed and translocated in brain and lung cancers. In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70\% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.",

keywords = "CMML, Chronic myeloproliferative neoplasms, Molecular target, Proliferation, ROS1, Tyrosine kinase",

author = "Daniela Cilloni and Sonia Carturan and Enrico Bracco and Valentina Campia and Valentina Rosso and Davide Torti and Chiara Calabrese and Valentina Gaidano and Pimjai Niparuck and Alessandra Favole and Elisabetta Signorino and Ilaria Iacobucci and Annalisa Morano and \{De Luca\}, Luciana and Pellegrino Musto and Francesco Frassoni and Giuseppe Saglio",

year = "2013",

month = may,

doi = "10.1016/j.leukres.2013.01.014",

language = "English",

volume = "37",

pages = "520--530",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "5",

}

Cilloni, D, Carturan, S, Bracco, E, Campia, V, Rosso, V, Torti, D, Calabrese, C, Gaidano, V, Niparuck, P, Favole, A, Signorino, E, Iacobucci, I, Morano, A, De Luca, L, Musto, P, Frassoni, F & Saglio, G 2013, 'Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia', Leukemia Research, vol. 37, no. 5, pp. 520-530. https://doi.org/10.1016/j.leukres.2013.01.014

TY - JOUR

T1 - Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia

AU - Cilloni, Daniela

AU - Carturan, Sonia

AU - Bracco, Enrico

AU - Campia, Valentina

AU - Rosso, Valentina

AU - Torti, Davide

AU - Calabrese, Chiara

AU - Gaidano, Valentina

AU - Niparuck, Pimjai

AU - Favole, Alessandra

AU - Signorino, Elisabetta

AU - Iacobucci, Ilaria

AU - Morano, Annalisa

AU - De Luca, Luciana

AU - Musto, Pellegrino

AU - Frassoni, Francesco

AU - Saglio, Giuseppe

PY - 2013/5

Y1 - 2013/5

N2 - Chronic myelomonocytic leukemia (CMML) is a clonal disorder sharing features of myelodysplastic syndromes and chronic myeloproliferative neoplasms. Although rare chromosomal aberrations and point mutations are reported in CMML, the molecular defects underlying CMML are largely unknown. ROS1 encodes a tyrosine kinase that is abnormally expressed and translocated in brain and lung cancers. In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.

AB - Chronic myelomonocytic leukemia (CMML) is a clonal disorder sharing features of myelodysplastic syndromes and chronic myeloproliferative neoplasms. Although rare chromosomal aberrations and point mutations are reported in CMML, the molecular defects underlying CMML are largely unknown. ROS1 encodes a tyrosine kinase that is abnormally expressed and translocated in brain and lung cancers. In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target.

KW - CMML

KW - Chronic myeloproliferative neoplasms

KW - Molecular target

KW - Proliferation

KW - ROS1

KW - Tyrosine kinase

UR - https://www.scopus.com/pages/publications/84875889772

U2 - 10.1016/j.leukres.2013.01.014

DO - 10.1016/j.leukres.2013.01.014

M3 - Article

C2 - 23415111

AN - SCOPUS:84875889772

SN - 0145-2126

VL - 37

SP - 520

EP - 530

JO - Leukemia Research

JF - Leukemia Research

IS - 5

ER -

Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this